NVOS Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -86.61% compared to Novo Integrated Sciences, Inc.'s net margin of 0.11%. Novo Integrated Sciences, Inc.'s return on equity of -49.15% beat Astrana Health, Inc.'s return on equity of 1.85%.

Novo Integrated Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Astrana Health, Inc. has an analysts' consensus of $35.6667 which suggests that it could grow by 89.92%. Given that Astrana Health, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe Astrana Health, Inc. is more attractive than Novo Integrated Sciences, Inc..

Novo Integrated Sciences, Inc. has a beta of 1.479, which suggesting that the stock is 47.909% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.555%.

Novo Integrated Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Integrated Sciences, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Novo Integrated Sciences, Inc. quarterly revenues are $3.2M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Novo Integrated Sciences, Inc.'s net income of -$2.7M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Novo Integrated Sciences, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 98.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences, Inc. is 0.00x versus 0.32x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -86.61% compared to Novo Integrated Sciences, Inc.'s net margin of 9.58%. Novo Integrated Sciences, Inc.'s return on equity of -49.15% beat Cryo-Cell International, Inc.'s return on equity of --.

Novo Integrated Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 148.03%. Given that Cryo-Cell International, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Novo Integrated Sciences, Inc..

Novo Integrated Sciences, Inc. has a beta of 1.479, which suggesting that the stock is 47.909% more volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.701, suggesting its less volatile than the S&P 500 by 29.861%.

Novo Integrated Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.97% to investors and pays a quarterly dividend of $0.15 per share. Novo Integrated Sciences, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Novo Integrated Sciences, Inc. quarterly revenues are $3.2M, which are smaller than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Novo Integrated Sciences, Inc.'s net income of -$2.7M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Novo Integrated Sciences, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences, Inc. is 0.00x versus 0.88x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of -86.61% compared to Novo Integrated Sciences, Inc.'s net margin of 14.05%. Novo Integrated Sciences, Inc.'s return on equity of -49.15% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Novo Integrated Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Novo Integrated Sciences, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Novo Integrated Sciences, Inc. is more attractive than Pacific Health Care Organization, Inc..

Novo Integrated Sciences, Inc. has a beta of 1.479, which suggesting that the stock is 47.909% more volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Novo Integrated Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Novo Integrated Sciences, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Novo Integrated Sciences, Inc. quarterly revenues are $3.2M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Novo Integrated Sciences, Inc.'s net income of -$2.7M is lower than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Novo Integrated Sciences, Inc.'s price-to-earnings ratio is -- while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences, Inc. is 0.00x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of -86.61% compared to Novo Integrated Sciences, Inc.'s net margin of -38.91%. Novo Integrated Sciences, Inc.'s return on equity of -49.15% beat WW International's return on equity of --.

Novo Integrated Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than Novo Integrated Sciences, Inc., analysts believe WW International is more attractive than Novo Integrated Sciences, Inc..

Novo Integrated Sciences, Inc. has a beta of 1.479, which suggesting that the stock is 47.909% more volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.

Novo Integrated Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Integrated Sciences, Inc. pays -- of its earnings as a dividend. WW International pays out -- of its earnings as a dividend.

Novo Integrated Sciences, Inc. quarterly revenues are $3.2M, which are smaller than WW International quarterly revenues of $186.6M. Novo Integrated Sciences, Inc.'s net income of -$2.7M is higher than WW International's net income of -$72.6M. Notably, Novo Integrated Sciences, Inc.'s price-to-earnings ratio is -- while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Integrated Sciences, Inc. is 0.00x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.